QNDPF yields 5.59% · PFE yields 6.13%● Live data
📍 QNDPF pulled ahead of the other in Year 1
Combined, QNDPF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QNDPF + PFE for your $10,000?
Qingdao Port International Co., Ltd. operates the Port of Qingdao. It operates through six segments: Container Handling and Ancillary Services; Metal Ores, Coal and Other Cargo Handling and Ancillary Services; Liquid Bulk Handling and Ancillary Services; Logistics and Port Value-Added Services; Port Ancillary Services; and Financial Services. The company is involved in the loading and discharging of containers, metal ores, coal, grains, and break bulk and liquid bulk cargos, as well as other general cargos. It also provides storage services; and port management, container freight station, cargo logistics, agency, towing, tallying, facilities construction, and other services. In addition, the company manufactures port related equipment; and supplies electricity power, fuel, and other products. Further, it offers port machinery manufacture, construction, tugboat and barging, and ocean shipping tallying services; and security, emergency, stevedoring and handling, and textile and apparel services. Additionally, the company provides financial products and services comprising deposit taking, guarantee, insurance agency, and investment and financial management services, as well as corporate loans; and shipping repair and agency, engineering and construction, cargo and trade agency, engineering design, technology, property management, media, lightering, oil pipeline transportation, and check and inspection services. It also engages in the LNG operations. As of December 31, 2021, it operated 92 berths at the Port of Qingdao. The company was incorporated in 2013 and is headquartered in Qingdao, the People's Republic of China. Qingdao Port International Co., Ltd. operates as a subsidiary of Shandong Qingdao Port Group Co., Ltd.
Full QNDPF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.